Our global network spans the U.S., Europe and Asia, with cGMP-compliant facilities in Seattle, Washington Boulder, Colorado Copenhagen, Denmark Heidelberg, Germany Milan, Italy and Chiba, Japan and we currently employ more than 1,700 employees worldwide. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), viral vectors and genetically engineered cells. AGC Biologics is now one of the very few CDMOвЂ™s in the world offering both plasmid production and end-to-end cell and gene therapy services.ДЄGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. The site was the first GMP facility approved in Europe for ex-vivo gene therapy manufacturing and has industry-unique commercial manufacturing experience, with two cell & gene therapy products. The award comes two months after the announcement of an expansion to the Cell and Gene Therapy Center of Excellence in Milan. вЂњItвЂ™s truly the combination of AGCвЂ™s business acumen and the former MolMedвЂ™s Cell and Gene Therapy technical acumen that made this partnership so strong from the beginning.вЂќ вЂњThe deal emerged after a mutual search that would allow both companies to converge in a Cell and Gene Therapy sector backed by unlimited potential,вЂќ says AGC Biologics General Manager, Milan, Luca Alberici. Chris Allen, This is the pool system you need to have.

The award was received by Luca Alberici, AGC Biologics General Manager, Milan, in a virtual ceremony on May 13, 2021, which was hosted by Andrea Cabrini, Director of Class CNBC. AGC of Oklahoma - Building Chapter -More activity by Stephen Chris Allen, This is the pool system you need to have.

The Award Jury, which met in early 2021, ranked the AGC-MolMed acquisition first in the Foreign Category (Cross Border into Italy), and shared their high praises and congratulations. вЂњA tremendous amount of care and skill went into this acquisition from both of the teams at AGC and the former MolMed, and weвЂ™re thrilled to be working together as one вЂ“ continually innovating to meet the growing needs of our customers and their patients.вЂќ вЂњWe are incredibly honored to have received this award,вЂќ says AGC Biologics Chief Executive Officer, Patricio Massera. This award is dedicated to showcasing the best of the Italian M&A market. Seattle, (GLOBE NEWSWIRE) - AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced their win of the M&A Award for Best Acquisition, Cross-Border into Italy, presented by KPMG, Fineurop Soditic, and others.

Agc win500